Doravirine

Routes
Oral (PO)
Half-Life (t½)
PO: 15h
Formula
C17H11ClF3N5O3
Molecular Weight
425.74 g/mol
PubChem CID
58460047
Aliases
Pifeltro

Pharmacological Mechanism

Newer NNRTI with cleaner DDI profile (CYP3A4 substrate but minimal induction). Lower psychiatric side effect signal than efavirenz. Used in DOR/3TC/TDF (Delstrigo) once-daily regimen.

Half-Life & Elimination Curve (PO: 15h)

100%50%25%12.5%0%0h0×t½15h1×t½30h2×t½45h3×t½60h4×t½3.1d5×t½0×t½ (0h): 100% remaining (~0.837 mg/L)1×t½ (15h): 50% remaining (~0.418 mg/L)2×t½ (30h): 25% remaining (~0.209 mg/L)3×t½ (45h): 12.5% remaining (~0.105 mg/L)4×t½ (60h): 6.3% remaining (~52.3 µg/L)5×t½ (3.1d): 3.1% remaining (~26.2 µg/L)
Plasma (PO)t½ Decay (15h)
  • 0×t½0h100% (0.837 mg/L)
  • 1×t½15h50% (0.418 mg/L)
  • 2×t½30h25% (0.209 mg/L)
  • 3×t½45h12.5% (0.105 mg/L)
  • 4×t½60h6.3% (52.3 µg/L)
  • 5×t½3.1d3.1% (26.2 µg/L)
Elimination t½15h (PO)
Rate Constant (ke)0.0462 h⁻¹
Time to Peak (Tmax)5.25h
Est. Peak (Cmax)0.837 mg/L
Clearance (CL)2.77 L/h
97% Washout (5×t½)3.1d

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References